ENT/Head and Neck Cancers

AV-299-23-301

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FICLATUZUMAB IN COMBINATION WITH CETUXIMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HPV-NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA (FIERCE-HN)

Open at Paris since : 05/12/2024
Target : Adult
Phase : Phase III

Trial description

To compare the efficacy by overall survival of ficlatuzumab plus cetuximab vs placebo plus cetuximab in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).Overall survival (OS), defined as the time from the date of randomization to the date of death for any cause.

Url of the trial

Main investigator

CHRISTOPHE LE TOURNEAU

Professeur - Médecin

Contact